Janus Henderson Group PLC Acadia Pharmaceuticals Inc Transaction History

Janus Henderson Group PLC

$194 Billion
Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 43,124 shares of ACAD stock, worth $980,639. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,124

Previous 425,903 89.87%

Holding current value

$980,639

Previous $7.07 Million 86.85%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$14.1 - $22.95 $5.4 Million - $8.78 Million	-382,779 Reduced 89.87%	43,124 $930,000
Q1 2025 May 15, 2025	BUY	$16.61 - $20.29 $6.2 Million - $7.57 Million	373,079 Added 706.27%	425,903 $7.07 Million
Q2 2024 Aug 14, 2024	SELL	$14.62 - $18.42 $12,163 - $15,325	-832 Reduced 1.55%	52,824 $858,000
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $35 - $61	2 Added 0.0%	53,656 $992,000
Q4 2023 Feb 14, 2024	SELL	$20.78 - $31.77 $2,576 - $3,939	-124 Reduced 0.23%	53,654 $1.68 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $250 - $401	12 Added 0.02%	53,778 $1.12 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $2,990 - $4,309	168 Added 0.31%	53,766 $1.29 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $476,821 - $611,219	29,217 Added 119.84%	53,598 $1.01 Million
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $14 - $18	-1 Reduced -0.0%	24,381 $388,000
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $4,472 - $5,791	-317 Reduced 1.28%	24,382 $398,000
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $29.5 Million - $61.8 Million	-2,270,577 Reduced 98.92%	24,699 $348,000
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $5.41 Million - $7.1 Million	258,295 Added 12.68%	2,295,276 $55.6 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $1.43 Million - $2.31 Million	85,123 Added 4.36%	2,036,981 $47.5 Million
Q3 2021 Nov 16, 2021	BUY	$15.78 - $24.77 $358,632 - $562,947	22,727 Added 1.18%	1,951,858 $32.4 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $66.9 Million - $94.6 Million	-3,448,245 Reduced 64.13%	1,929,131 $47.1 Million
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $7.37 Million - $16.2 Million	294,464 Added 5.79%	5,377,376 $139 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $25.6 Million - $35.4 Million	-623,192 Reduced 10.92%	5,082,912 $272 Million
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $65.4 Million - $102 Million	1,796,141 Added 45.94%	5,706,104 $235 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $95 Million - $128 Million	2,420,061 Added 162.43%	3,909,963 $190 Million
Q1 2020 May 14, 2020	BUY	$31.65 - $46.87 $47.2 Million - $69.8 Million	1,489,902 New	1,489,902 $62.9 Million
Q4 2019 Feb 18, 2020	SELL	$36.21 - $51.4 $3.76 Million - $5.34 Million	-103,894 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $2.31 Million - $4.57 Million	103,894 New	103,894 $0
Q1 2019 Apr 30, 2019	SELL	$16.17 - $27.38 $50.8 Million - $86 Million	-3,142,042 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$14.32 - $22.92 $10,625 - $17,006	-742 Reduced 0.02%	3,142,042 $50.8 Million
Q3 2018 Nov 09, 2018	SELL	$13.03 - $21.81 $3.98 Million - $6.67 Million	-305,826 Reduced 8.87%	3,142,784 $65.2 Million
Q2 2018 Aug 10, 2018	SELL	$15.07 - $22.34 $53.5 Million - $79.2 Million	-3,546,991 Reduced 50.7%	3,448,610 $52.7 Million
Q1 2018 May 14, 2018	BUY	$22.47 - $32.33 $4.82 Million - $6.93 Million	214,317 Added 3.16%	6,995,601 $157 Million
Q4 2017 Feb 09, 2018	BUY	$26.84 - $39.14 $22.1 Million - $32.2 Million	822,736 Added 13.81%	6,781,284 $204 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $67.7 Million - $88.1 Million	2,295,881 Added 62.68%	5,958,548 $0
Q2 2017 Aug 17, 2017	BUY	N/A	3,662,667	3,662,667 $102 Million

Others Institutions Holding ACAD

# of Institutions

350

Shares Held

164M

Call Options Held

811K

Put Options Held

334K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.68B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Acadia Pharmaceuticals Inc Transaction History